6 Recommendations Regarding HTAs in the United States
A whitepaper was recently released by researchers at the USC Schaeffer Center and the Aspen Institute. The authors discuss half [...]
A Conversation with Peter Pitts on Drug Pricing and Medicare
In a recent podcast by Patients Rising Podcast, the hosts spoke with Peter Pitts. He co-founded and is currently president [...]
Outcry Over Nick Jonas in Super Bowl Commercial for Dexcom
Type 1 Diabetics typically check their blood glucose levels by pricking their finger with a needle to obtain a small [...]
Growing Support for HTA in Light of High Gene Therapy Costs
An independent review board, such as ICER, responsible for assessing appropriate costs for therapies and drugs has been discussed for [...]
ICER Releases Draft Evidence Report for Several Multiple Myeloma Therapies: Will These Drugs Prevent Relapse?
ICER has released a report on three therapies for multiple myeloma: belantamab mafodotin blmf from Blenrep™ and GlaxoSmithKline, idecabtagene vicleucel [...]
[Whitepaper] Understanding and Using SDOH Data
SDOH (social determinants of health) data can be incredibly valuable. While these data can be immensely useful in reducing medical [...]
Tenacious Sheila McLean Joins Patients for Affordable Drugs
Sheila Mclean began her position as Executive Director of Patients for Affordable Drugs in January 2021. In her new role, [...]
PhRMA Details Concerns Over Recent HHS Ruling
The Department of Health and Human Services (HHS) released a mid-January ruling relating to insurance enrollment, changes to the Premium [...]
Science Invites Insight on 20th Anniversary of Human Genome Sequencing Project
Leading journal Science invited researchers to share insight into data integrity, polygenic disease risk, ethics related to genomics, the downfalls [...]
Governor Baker Estimates $70 Million in Overcharging Penalties
A 2022 budget proposal released by Governor Charlie Baker estimates that $70 million will be collected from pharmaceutical companies for [...]
ICER Evidence Report for Inclisiran Released
Inclisiran by Novartis may be priced lower than other drugs targeting LDL cholesterol. Now that ICER has released its pricing [...]
Local Officials Join in Fight Against High Drug Prices
High drug costs in the US result from a number of factors and face criticism from many different parties. Recently, [...]
Cytel’s Advanced Design Framework to Improve Clinical Trials
Cytel has released its Advanced Design Framework as a method to minimize failed clinical trials. Ideally, biostatisticians are involved in [...]
Are Budget Caps a Solution to Skyrocketing Health Costs?
Healthcare costs and access to health services continue to be major points of discussion. One proposed solution is that of [...]
Yes–Prescription Costs are Much Higher in the United States
According to a recent article, there are serious discrepancies in drug prices between the United States and many other countries. [...]
Online Healthcare Pricing Information Unclear and Confusing
Healthcare systems and hospitals posted pricing information for their services beginning January 1st. However, consistency across hospital systems remains lacking. [...]
Use of Real-world Evidence in Economic Assessments of Pharmaceuticals in the US
In a recent study, investigators from the University of Washington School of Pharmacy reviewed cost-effectiveness and budget impact analyses in [...]
The Patient Not in the Room
Since 2009, the amount that workers pay for health insurance has increased 71% while wages have increased 26%--yet another demonstration [...]
ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]
New Study Examines Perspective and Costing in Cost-Effectiveness Analysis
A recent study examined perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness [...]
How is the Institute for Clinical and Economic Review (ICER) Incorporating the Patient’s Voice in Value Assessments?
Evaluating the cost-effectiveness of interventions with value assessment frameworks continues to gain traction in US healthcare. Now attention is shifting [...]
Article: ICER’s Judgements ‘Anchored by Cost-Effectiveness’
The authors of a recent article suggest that Institute for Clinical and Economic Review (ICER) council members' judgements are ultimately [...]
ASH Outlines Ins and Outs of Cost-Effective Analyses
In its cover article for the March edition of the ASH Clinical News magazine, ASH takes a deep dive into [...]